StockClub

NAMS

NAMSNewAmsterdam Pharma Company N.V.$ --
NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V.

NAMS

$ -

-

Review earnings summary, surprise history, and upcoming forecasts.

wallet
Earnings Summary
Updated: 03/31/2026FY2026 Q1
Revenue
3M USD
YoY +2.1%
Operating Income
-58M USD
YoY +15.2%
Net Income
-48M USD
YoY -22.6%
EPS
-0.4$
YoY -17.6%

Revenue

$3M
FY2024 Q2$3.7M
$3.7M
Q2
FY2024 Q3$32.8M
$32.8M
Q3
FY2024 Q4$45.6M
$45.6M
Q4
FY2025 Q1$3M
$3M
Q1
FY2025 Q2$22.1M
$22.1M
Q2
FY2025 Q3$22.5M
$22.5M
Q3
FY2025 Q4$22.5M
$22.5M
Q4
FY2026 Q1$3M
$3M
Q1
Actual
+$62,000 (+2.1%)

Net Income

$-48.4M
FY2024 Q2$-132.8M
$-132.8M
Q2
FY2024 Q3$-149.4M
$-149.4M
Q3
FY2024 Q4$-241.6M
$-241.6M
Q4
FY2025 Q1$-39.5M
$-39.5M
Q1
FY2025 Q2$-56.9M
$-56.9M
Q2
FY2025 Q3$-128.9M
$-128.9M
Q3
FY2025 Q4$-203.8M
$-203.8M
Q4
FY2026 Q1$-48.4M
$-48.4M
Q1
Actual
$-8.9M (-22.6%)

Surprise History

Actual RevenueAnalyst Estimate
FY2020
Actual:$0
FY2020
$0
FY2021
Actual:$0
FY2021
$0
FY2022MISS
Actual:$102.7M
Est:$113M
FY2022MISS
$102.7M
FY2023MISS
Actual:$14.1M
Est:$14.4M
FY2023MISS
$14.1M
FY2024BEAT
Actual:$45.6M
Est:$33.8M
FY2024BEAT
$45.6M
FY2025MISS
Actual:$22.5M
Est:$24M
FY2025MISS
$22.5M

Analyst Estimates